A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

• Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least:
• 12 months s if participants are ≥6 years of age, and
• 6 months if participants are 6 months to <6 years of age
• Have an EASI score ≥16 at the screening and baseline
• Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline
• Have ≥10% BSA of AD involvement at the screening and baseline.

Exclusion Criteria:

• Are currently enrolled or have participated within the last 8 weeks in a clinicalstudy involving an investigational intervention or any other type of medical researchjudged not to be scientifically or medically compatible with this study.
• Treatment with the following prior to the baseline:
• An investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.
• Dupilumab within 8 weeks. Note: The enrollment of participants with prior use ofDupilumab will be limited to <20%.
• Treatment with a topical investigational drug within 2 weeks prior to the baseline.
• Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4weeks before randomization.